Leap Therapeutics Stock Analysis
| LPTX Stock | USD 0.52 0.05 8.77% |
Leap Therapeutics is undervalued with Real Value of 2.84 and Target Price of 9.83. The main objective of Leap Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Leap Therapeutics is worth, separate from its market price. There are two main types of Leap Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Leap Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Leap Therapeutics is usually not traded on Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, National Mourning Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day. Leap Stock trading window is adjusted to America/New York timezone.
Leap |
Leap Stock Analysis Notes
About 17.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 0.45. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Leap Therapeutics has Price/Earnings To Growth (PEG) ratio of 0.75. The entity recorded a loss per share of 1.64. The firm had not issued any dividends in recent years. Leap Therapeutics had 1:10 split on the 21st of June 2023. Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts. Leap Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 36 people. To find out more about Leap Therapeutics contact the company at 617 714 0360 or learn more at https://www.leaptx.com.Leap Therapeutics Investment Alerts
| Leap Therapeutics generated a negative expected return over the last 90 days | |
| Leap Therapeutics has high historical volatility and very poor performance | |
| Leap Therapeutics has some characteristics of a very speculative penny stock | |
| Net Loss for the year was (81.41 M) with profit before overhead, payroll, taxes, and interest of 1.5 M. | |
| Leap Therapeutics currently holds about 90.88 M in cash with (43.75 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.92, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Leap Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Roughly 17.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from news.google.com: Baird cuts Leap Therapeutics stock rating, slashes target - MSN |
Leap Therapeutics Upcoming and Recent Events
Earnings reports are used by Leap Therapeutics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period..
| 22nd of March 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 22nd of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Leap Largest EPS Surprises
Earnings surprises can significantly impact Leap Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2022-05-13 | 2022-03-31 | -0.1 | -0.09 | 0.01 | 10 | ||
2021-11-12 | 2021-09-30 | -0.11 | -0.14 | -0.03 | 27 | ||
2020-11-12 | 2020-09-30 | -0.13 | -0.09 | 0.04 | 30 |
Leap Stock Institutional Investors
| Shares | Exome Asset Management Llc | 2024-09-30 | 205.3 K | Blackrock Inc | 2024-09-30 | 203 K | Ubs O'connor Llc | 2024-09-30 | 165.1 K | Longwood Capital Partners Llc | 2024-09-30 | 120.5 K | Dimensional Fund Advisors, Inc. | 2024-09-30 | 81.5 K | State Street Corp | 2024-09-30 | 71.8 K | Susquehanna International Group, Llp | 2024-09-30 | 66.2 K | Northern Trust Corp | 2024-09-30 | 61.6 K | Marshall Wace Asset Management Ltd | 2024-09-30 | 52.9 K | Balyasny Asset Management Llc | 2024-09-30 | 3.1 M | Samsara Biocapital, Llc | 2024-09-30 | 2.4 M |
Leap Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 21.9 M.Leap Profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.29) | (1.35) | |
| Return On Capital Employed | (1.30) | (1.24) | |
| Return On Assets | (1.29) | (1.35) | |
| Return On Equity | (1.22) | (1.16) |
Management Efficiency
Leap Therapeutics has return on total asset (ROA) of (0.4562) % which means that it has lost $0.4562 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8054) %, meaning that it created substantial loss on money invested by shareholders. Leap Therapeutics' management efficiency ratios could be used to measure how well Leap Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.35 in 2025. Return On Capital Employed is likely to rise to -1.24 in 2025. At this time, Leap Therapeutics' Non Current Assets Total are fairly stable compared to the past year. Non Currrent Assets Other is likely to rise to about 1.3 M in 2025, whereas Total Assets are likely to drop slightly above 45.2 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 3.38 | 3.21 | |
| Tangible Book Value Per Share | 3.38 | 3.21 | |
| Enterprise Value Over EBITDA | (0.16) | (0.17) | |
| Price Book Value Ratio | 1.62 | 1.41 | |
| Enterprise Value Multiple | (0.16) | (0.17) | |
| Price Fair Value | 1.62 | 1.41 | |
| Enterprise Value | 16.4 M | 15.6 M |
Understanding the operational decisions made by Leap Therapeutics management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Technical Drivers
As of the 31st of January, Leap Therapeutics secures the Risk Adjusted Performance of (0.13), mean deviation of 5.58, and Standard Deviation of 10.63. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Leap Therapeutics, as well as the relationship between them.Leap Therapeutics Price Movement Analysis
The output start index for this execution was fourty-four with a total number of output elements of seventeen. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Leap Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Leap Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Leap Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Leap Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Leap Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Leap Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Leap Therapeutics Outstanding Bonds
Leap Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Leap Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Leap bonds can be classified according to their maturity, which is the date when Leap Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| LEAR P 38 Corp BondUS521865AY17 | View | |
| US521865AZ81 Corp BondUS521865AZ81 | View | |
| US521865BB05 Corp BondUS521865BB05 | View | |
| LEA 26 15 JAN 32 Corp BondUS521865BC87 | View | |
| LEA 355 15 JAN 52 Corp BondUS521865BD60 | View | |
| US521865BA22 Corp BondUS521865BA22 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View |
Leap Therapeutics Predictive Daily Indicators
Leap Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Leap Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 205279.0 | |||
| Daily Balance Of Power | (0.83) | |||
| Rate Of Daily Change | 0.91 | |||
| Day Median Price | 0.54 | |||
| Day Typical Price | 0.53 | |||
| Price Action Indicator | (0.04) | |||
| Period Momentum Indicator | (0.05) |
Leap Therapeutics Forecast Models
Leap Therapeutics' time-series forecasting models are one of many Leap Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Leap Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Leap Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Leap Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Leap shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Leap Therapeutics. By using and applying Leap Stock analysis, traders can create a robust methodology for identifying Leap entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (31.14) | (32.69) | |
| Operating Profit Margin | (31.76) | (33.35) | |
| Net Loss | (31.12) | (32.67) |
Current Leap Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Leap analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Leap analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Advice | # of Analysts | |
| 9.83 | Strong Buy | 3 | Odds |
Most Leap analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Leap stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Leap Therapeutics, talking to its executives and customers, or listening to Leap conference calls.
Leap Stock Analysis Indicators
Leap Therapeutics stock analysis indicators help investors evaluate how Leap Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Leap Therapeutics shares will generate the highest return on investment. By understating and applying Leap Therapeutics stock analysis, traders can identify Leap Therapeutics position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 65.5 M | |
| Common Stock Shares Outstanding | 20.4 M | |
| Total Stockholder Equity | 60.1 M | |
| Property Plant And Equipment Net | 262 K | |
| Cash And Short Term Investments | 70.6 M | |
| Cash | 70.6 M | |
| Accounts Payable | 6.5 M | |
| Net Debt | -70.4 M | |
| 50 Day M A | 2.8466 | |
| Total Current Liabilities | 12.7 M | |
| Other Operating Expenses | 87 M | |
| Non Current Assets Total | 1.2 M | |
| Non Currrent Assets Other | 966 K | |
| Stock Based Compensation | 5.1 M |
Additional Tools for Leap Stock Analysis
When running Leap Therapeutics' price analysis, check to measure Leap Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Leap Therapeutics is operating at the current time. Most of Leap Therapeutics' value examination focuses on studying past and present price action to predict the probability of Leap Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Leap Therapeutics' price. Additionally, you may evaluate how the addition of Leap Therapeutics to your portfolios can decrease your overall portfolio volatility.